The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NEUP | +36.77% | N/A | N/A | +132% |
| S&P | +15.06% | +95.03% | +14.29% | +12% |
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
| Q1 2025 | YOY Change | |
|---|---|---|
| Revenue | $15.00M | 0.0% |
| Gross Profit | $14.83M | 9052.5% |
| Gross Margin | 98.90% | 0.0% |
| Market Cap | $10.12M | 1002.7% |
| Net Income | $11.26M | 505.4% |
| EBITDA | $12.14M | 644.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2025 | YOY Change | |
|---|---|---|
| Net Cash | $17.04M | 0.0% |
| Accounts Receivable | $0.10M | 0.0% |
| Inventory | 0 | 0.0% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.02M | 0.0% |
| Short Term Debt | $0.15M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -54.23% | -9.2% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $11.22M | 435.0% |
| Operating Free Cash Flow | $11.22M | 435.0% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 74.52 | 80.24 | 625.91 | 0.68 | -99.32% |
| Price to Sales | 8.15 | 0.63 | - | ||
| Price to Tangible Book Value | 19.05 | 31.37 | 3733.09 | 45.86 | 79.26% |
| Price to Free Cash Flow TTM | 21.24 | - | |||
| Enterprise Value to EBITDA | 2.16 | -360.31 | -0.35 | -0.57 | - |
| Free Cash Flow Yield | 4.7% | - | |||
| Total Debt | $0.27M | $0.25M | $0.17M | $0.17M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
